Back to results
US 2022/0249710 A1Published application
Bioreductively-activated compounds, their prodrugs, radiopharmaceuticals, the compositions, and their applications in multimodal theranostic management of hypoxia diseases including cancer
AssigneeThe Governors of the University of Alberta
InventorsPiyush KUMAR, Hassan ELSAIDI, Leonard Irving WIEBE, Michael WEINFELD, Carolynne Lacar RICARDO
Life of this patent
Estimating the term…
Abstract
Described herein are bioreductively-activated compounds, their prodrugs, radiopharmaceuticals, the compositions, and their application in multimodal theranostic management of hypoxia diseases including cancer.
Claims9
A compound of formula (I), or any prodrug, pharmaceutically acceptable salt, metabolite, polymorph, solvate, hydrate, stereoisomer, radioisotope, or tautomer thereof:
- wherein BA comprises one or more of 2/4/5-substituted nitroimidazoles, substituted benzotriazene-1,4-dioxides, substituted 1,2,3/1,2,4-triazoles, substituted 1,4-benzoquinones, or combination of two homo- or hetero BA moieties,
- wherein Linker Arm is —C1-16 alkane, alkene, alkyne, alicyclic, aromatic with or without hetero atoms as in ethers, amines, esters, acids, amides;
- 5 and 6 membered rings with the substitutions as described above, both monosaccharides and disaccharides,
- wherein the (Radio)theranostic Arm comprises 18/19F, 123/124/125/127/131I, Lu-177, Ga-68, 99mTC, etc.
1 more element
Dependencies are inferred from the claim text.